How Much Weight Can You Actually Lose on Wegovy?

What STEP 1 actually found, and what the headline number leaves out

The STEP 1 trial, published in the New England Journal of Medicine in 2021, followed 1,961 adults with obesity or overweight plus a weight-related condition over 68 weeks. At the 2.4 mg weekly dose, participants lost an average of around 15% of body weight. That average gets quoted a lot, and it is clinically significant. But the average obscures how wide the range really was.

At one end, some participants lost very little. At the other, roughly a third lost 20% or more, and a smaller group lost upward of 25%. The question of what is the most weight lost on Wegovy, taken literally, is a difficult one to answer from published trial data, because papers report means and percentiles rather than the single highest individual loss. What is clear is that 20%-plus is achievable for a substantial minority, not a statistical outlier.

There is a common misconception worth setting down gently: that the 15% figure is the most you can expect. It is not a cap. It is the centre of a wide distribution. Where any individual falls on that curve depends on factors a prescriber will discuss with you, starting weight, dose tolerability, how consistently the lifestyle changes are sustained, and biology that nobody can fully predict in advance.

For further context on how timing affects the results you see, the pattern of when weight loss tends to peak on Wegovy is worth reading alongside this page.

The 7.2 mg dose and what newer evidence adds

In January 2026 a higher Wegovy dose entered the picture. The MHRA approved 7.2 mg semaglutide for weight management, initially as three 2.4 mg pens per week, and then on 14 April 2026 approved a dedicated single-dose 7.2 mg Wegovy pen. Trials at this higher dose reported average weight loss of roughly 20.7% over 72 weeks, a meaningful step up from the 2.4 mg results and substantially closer to what tirzepatide produces at its highest dose.

The 7.2 mg licence is for adults with a BMI of 30 or above only; it does not extend to the 27–29.9 BMI bracket that the 2.4 mg dose covers. The starting point is still 0.25 mg, titrated by the prescriber through the established schedule. No patient goes straight to 7.2 mg. That titration structure matters: the dose exists to be reached, not started at.

It is also worth noting that Wegovy is not the only semaglutide product. Ozempic contains the same active ingredient but is licensed for type 2 diabetes, not weight management. They are not interchangeable, and a prescriber assessing you for weight loss will work from the licensed Wegovy pathway. You can read a broader overview of how semaglutide works for weight management on the semaglutide information page.

Why the numbers differ so much between individuals

Clinical trial averages smooth over real human variation. Several factors genuinely influence how much weight any person loses on Wegovy, and none of them are fully in anyone's control.

Dose and duration matter most in the published data. People who reached and stayed at the 2.4 mg maintenance dose for the full trial period lost more weight, on average, than those who discontinued or remained at lower doses due to side effects. That is partly why the steps you take alongside the injection (protein adequacy, hydration, activity and consistency) are emphasised by prescribers, not as moral instruction, but because they appear in the evidence as meaningful modifiers.

Biology adds another layer. Insulin sensitivity, gut-hormone response, baseline metabolic rate and genetic factors all influence how strongly semaglutide's appetite-signalling effects translate into weight change. Two people on the same dose, following the same lifestyle plan, will not necessarily lose the same amount. That is not a failure of treatment; it is a feature of human physiology.

Side effect tolerance plays a role too. GI symptoms (nausea, constipation, and similar) are the most commonly reported adverse effects and can lead some people to slow their titration or stop. The full Wegovy overview covers what to expect as doses increase. Managing those early weeks well is where a clinical team earns its place.

If you have started treatment and the results so far are not what you expected, it is worth reading about why some people see slower progress before drawing conclusions.

Putting the evidence in a private-prescription context

NICE recommends semaglutide (Wegovy) under its guidance TA875 for eligible adults within specialist NHS weight management services, for a maximum of two years, with multidisciplinary support. NHS waiting lists for those services can be long, and the eligibility criteria are specific.

For people who do not meet NHS criteria or prefer not to wait, a private prescription is the legal alternative, but it still requires a full clinical assessment by a registered prescriber. The question of what private Wegovy costs is a practical one, and it is worth understanding what any price should include: consultation, clinical review, prescription and ongoing aftercare. Treatments prescribed without that framework are not just poor value; they carry real risks.

The NHS information on weight management injections sets out the clinical context clearly, including the contraception advice for women using oral contraceptives alongside Wegovy. That guidance is worth reading regardless of whether you access treatment privately or through the NHS.

If you are considering whether Wegovy is the right fit for your situation, checking your eligibility through a free consultation is the sensible next step. A GPhC-registered prescriber at nume reviews each consultation personally, the same day it is submitted.